ライフサイエンスコーパス: bone marrow biopsy

1 red with tryptase in estimating the need for bone marrow biopsy.

2 emic mastocytosis) and thus candidates for a bone marrow biopsy.

3 cell aggregates, and atypical mast cells on bone marrow biopsy.

4 fficient accuracy to replace routine staging bone marrow biopsy.

5 sponse to up to 31 drugs within 5 days after bone marrow biopsy.

6 , urine and serum immunoelectrophoresis, and bone marrow biopsy.

7 the diagnosis usually depends on results of bone marrow biopsy.

8 ng pure red cell aplasia (PRCA) confirmed by bone marrow biopsy.

9 pared with hematologic response criteria and bone marrow biopsies.

10 ot spot density compared with normal control bone marrow biopsies.

11 nical relevance of expression in 55 archival bone marrow biopsies.

12 e myeloid leukemia (AML) routinely undergo a bone marrow biopsy 7-10 days after induction chemotherap

13 Analysis of bone marrow biopsies after CTL019 revealed 8 patients wi

14 Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subseque

15 Bone marrow biopsy analysis showed 5% plasma cells, whic

16 nohistochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of mic

17 umbers of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothel

18 The patient's bone marrow biopsy and aspirate displayed unique patholo

19 enia and negligible gene marking, diagnostic bone marrow biopsy and aspirate were performed at day 88

20 A bone marrow biopsy and aspiration revealed a mildly hype

21 tiple myeloma was diagnosed and confirmed by bone marrow biopsy and aspiration.

22 Congo red stain on bone marrow biopsy and fat pad aspirate was negative for

23 cible ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or

24 cible ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or

25 work-up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical and histoche

26 agnosis, in the selection of those needing a bone marrow biopsy, and in the documentation of disease

27 ria to identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA i

28 s or suspicious lymphocytic infiltrates in a bone marrow biopsy as the sole suggestion of residual di

29 )At-radioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection.

30 The diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according

31 one-metastatic CRPC who underwent transiliac bone marrow biopsy between October 2007 and March 2010.

32 B-cell lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marro

33 Skin and bone marrow biopsies can thus be used to generate de nov

34 A percutaneous biopsy of the mass and bone marrow biopsy confirmed the diagnosis of primary ad

35 Serum paraproteins and/or light chains or bone marrow biopsy defined response.

36 araspinal mass was discovered, and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.

37 agrelide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who

38 Bone marrow biopsy exhibited mostly mixed patterns of sm

39 r urticaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggre

40 iogenesis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients.

41 We evaluated bone marrow biopsies from 40 children with newly diagnos

42 iption factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic

43 Evaluation of bone marrow biopsies from myeloma patients revealed a st

44 Moreover, analysis of bone marrow biopsies from myeloma patients reveals a pos

45 In bone marrow biopsies from patients with DBA or del(5q) m

46 simultaneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cy

47 nohistochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant

48 Although bone marrow biopsies in these patients showed increased

49 t optimal test indicating the necessity of a bone marrow biopsy in ISM-suspected patients.

50 commonly used test to estimate the need for bone marrow biopsy in patients suspected to have indolen

51 tumor DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogen

52 o detected by immunohistochemistry in normal bone marrow biopsies, indicating an in vivo function.

53 oring response to therapy; also, the role of bone marrow biopsy is being revisited.

54 A bone marrow biopsy is no longer indicated for the routin

55 Bone marrow biopsies largely replaced by PCa were analyz

56 Bone marrow biopsy may reveal hemophagocytosis and marro

57 aranase activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive

58 e to quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilit

59 this cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon fo

60 In this investigation, bone marrow biopsies of the anterior iliac crest were ex

61 Responses were assessed by bone marrow biopsy on day 15 of the first course and by

62 drome features with the exception that their bone marrow biopsy pathology revealed abundant neutrophi

63 Bone marrow biopsy performed in two of these five patien

64 g/gm Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, t

65 re staged using clinical assessment, CT, and bone marrow biopsy (RATHL stage).

66 Bone marrow biopsy revealed hypercellular marrow.

67 Bone marrow biopsy revealed no evidence of infectious or

68 MAC loads in bilateral bone marrow biopsy samples from 7 subjects were highly c

69 Serial bone marrow biopsies showed normalization of trilineage

70 Comparison with bone marrow biopsies showed that FDG-PET was not reliabl

71 Bone marrow biopsy showed 60% infiltration with lambda l

72 Immunohistochemistry of bone marrow biopsy showed an increased number of plasma

73 After histologic analysis of the bone marrow biopsy specimen, diagnosis of Waldenstrom ma

74 In this study, bone marrow biopsy specimens from 36 patients with T-cel

75 The TMA was constructed using pretreatment bone marrow biopsy specimens from 64 adult patients with

76 orulae were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichi

77 rum lgs, and immunohistochemical staining of bone marrow biopsy specimens.

78 Analysis of bone marrow-biopsy specimens obtained from two patients

79 Immunohistochemical analysis of bone marrow-biopsy specimens showed that only myeloma ce

80 These data suggest that bone marrow biopsy using antigen-targeted magnetic nanop

81 Bone marrow biopsy was done on day -7 to estimate radiat

82 s was nondiagnostic, and lumbar puncture and bone marrow biopsies were negative.

83 One hundred eighty-four bone marrow biopsies were obtained, and 48 had prostate

84 Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer

85 PDGFR-expressing tumor declined on serial bone marrow biopsies with combination therapy alone.